These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 33400975)

  • 61. Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia in a Newborn Treated With Remdesivir and Coronavirus Disease 2019 Convalescent Plasma.
    Hopwood AJ; Jordan-Villegas A; Gutierrez LD; Cowart MC; Vega-Montalvo W; Cheung WL; McMahan MJ; Gomez MR; Laham FR
    J Pediatric Infect Dis Soc; 2021 May; 10(5):691-694. PubMed ID: 33306130
    [TBL] [Abstract][Full Text] [Related]  

  • 62. New challenges to fighting COVID-19: Virus variants, potential vaccines, and development of antivirals.
    Chen J; Lu H
    Biosci Trends; 2021 May; 15(2):126-128. PubMed ID: 33746183
    [TBL] [Abstract][Full Text] [Related]  

  • 63. COVID-19: benefits and risks of passive immunotherapeutics.
    Gupta A; Karki R; Dandu HR; Dhama K; Bhatt ML; Saxena SK
    Hum Vaccin Immunother; 2020 Dec; 16(12):2963-2972. PubMed ID: 32962524
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak.
    Maciorowski D; Ogaugwu C; Durvasula SR; Durvasula R; Kunamneni A
    SLAS Discov; 2021 Mar; 26(3):311-329. PubMed ID: 33319627
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.
    Magyari F; Pinczés LI; Páyer E; Farkas K; Ujfalusi S; Diószegi Á; Sik M; Simon Z; Nagy G; Hevessy Z; Nagy B; Illés Á
    Ann Hematol; 2022 Oct; 101(10):2337-2345. PubMed ID: 35836007
    [TBL] [Abstract][Full Text] [Related]  

  • 66. COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine.
    Guan W; Lan W; Zhang J; Zhao S; Ou J; Wu X; Yan Y; Wu J; Zhang Q
    Virol Sin; 2020 Dec; 35(6):685-698. PubMed ID: 32997322
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients.
    Tirnea L; Bratosin F; Vidican I; Cerbu B; Turaiche M; Timircan M; Margan MM; Marincu I
    Medicina (Kaunas); 2021 Mar; 57(3):. PubMed ID: 33799535
    [No Abstract]   [Full Text] [Related]  

  • 68. Precision therapeutic targets for COVID-19.
    Krumm ZA; Lloyd GM; Francis CP; Nasif LH; Mitchell DA; Golde TE; Giasson BI; Xia Y
    Virol J; 2021 Mar; 18(1):66. PubMed ID: 33781287
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency.
    Lang-Meli J; Fuchs J; Mathé P; Ho HE; Kern L; Jaki L; Rusignuolo G; Mertins S; Somogyi V; Neumann-Haefelin C; Trinkmann F; Müller M; Thimme R; Umhau M; Quinti I; Wagner D; Panning M; Cunningham-Rundles C; Laubner K; Warnatz K
    J Clin Immunol; 2022 Feb; 42(2):253-265. PubMed ID: 34893946
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2.
    Taşlı NP; Gönen ZB; Kırbaş OK; Gökdemir NS; Bozkurt BT; Bayrakcı B; Sağraç D; Taşkan E; Demir S; Ekimci Gürcan N; Bayındır Bilgiç M; Bayrak ÖF; Yetişkin H; Kaplan B; Pavel STI; Dinç G; Serhatlı M; Çakırca G; Eken A; Aslan V; Yay M; Karakukcu M; Unal E; Gül F; Basaran KE; Ozkul Y; Şahin F; Jones OY; Tekin Ş; Özdarendeli A; Cetin M
    Front Immunol; 2022; 13():824378. PubMed ID: 35401544
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Potential mechanisms of action of convalescent plasma in COVID-19.
    Franchini M; Glingani C; Liumbruno GM
    Diagnosis (Berl); 2021 Nov; 8(4):413-420. PubMed ID: 33652503
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019.
    Hartog N; Holsworth A; Rajasekaran S
    Ann Allergy Asthma Immunol; 2021 Feb; 126(2):122-123. PubMed ID: 33161152
    [No Abstract]   [Full Text] [Related]  

  • 73. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
    Devos T; Geukens T; Schauwvlieghe A; Ariën KK; Barbezange C; Cleeren M; Compernolle V; Dauby N; Desmecht D; Grimaldi D; Lambrecht BN; Luyten A; Maes P; Moutschen M; Romano M; Seyler L; Nevessignsky MT; Vandenberghe K; van Griensven J; Verbeke G; Vlieghe E; Yombi JC; Liesenborghs L; Verhamme P; Meyfroidt G
    Trials; 2020 Nov; 21(1):981. PubMed ID: 33246499
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.
    Kaku Y; Kuwata T; Zahid HM; Hashiguchi T; Noda T; Kuramoto N; Biswas S; Matsumoto K; Shimizu M; Kawanami Y; Shimura K; Onishi C; Muramoto Y; Suzuki T; Sasaki J; Nagasaki Y; Minami R; Motozono C; Toyoda M; Takahashi H; Kishi H; Fujii K; Tatsuke T; Ikeda T; Maeda Y; Ueno T; Koyanagi Y; Iwagoe H; Matsushita S
    Cell Rep; 2021 Jul; 36(2):109385. PubMed ID: 34237284
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Convalescent Plasma for Pregnant Women with COVID-19: A Systematic Literature Review.
    Franchini M; Prefumo F; Grisolia G; Bergamini V; Glingani C; Pisello M; Presti F; Zaffanello M
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34206468
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Course of SARS-CoV-2 in a Patient After a Recent Kidney Transplant: A Literature Review on COVID-19 Therapy.
    Kędzierska-Kapuza K; Zielińska D; Matejak-Górska M; Durlik M
    Transplant Proc; 2021 May; 53(4):1194-1201. PubMed ID: 33892930
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Review of Anti-inflammatory and Antiviral Therapeutics for Hospitalized Patients Infected with Severe Acute Respiratory Syndrome Coronavirus 2.
    Chen JT; Ostermann M
    Crit Care Clin; 2022 Jul; 38(3):587-600. PubMed ID: 35667745
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Reducing transmission of SARS-CoV-2 with intranasal prophylaxis.
    Boiardi F; Stebbing J
    EBioMedicine; 2021 Jan; 63():103170. PubMed ID: 33340994
    [No Abstract]   [Full Text] [Related]  

  • 79. An update of anti-viral treatment of COVID-19.
    Şimşek-Yavuz S; Komsuoğlu Çelikyurt FI
    Turk J Med Sci; 2021 Dec; 51(SI-1):3372-3390. PubMed ID: 34391321
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A consideration of convalescent plasma and plasma derivatives in the care of Severely-ill patients with COVID-19.
    Lung T; Kazatchkine MD; Risch L; Risch M; Nydegger UE
    Transfus Apher Sci; 2020 Oct; 59(5):102936. PubMed ID: 32919880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.